Although the discovery of the critical role of α-synuclein (α-syn) in the pathogenesis of
Parkinson's disease (PD) is now twenty-five years old, it still represents a milestone in PD …

Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a
global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both …

Targeted protein degradation allows targeting undruggable proteins for therapeutic
applications as well as eliminating proteins of interest for research purposes. While several …

Synucleinopathies are characterized by the accumulation of α-synuclein (α-Syn) aggregates
in the brain. Positron emission tomography (PET) imaging of synucleinopathies requires …

With the advent of the genetic era in Parkinson's disease (PD) research in 1997, α-synuclein
was identified as an important player in a complex neurodegenerative disease that affects> …

Parkinson disease (PD) follows a defined clinical pattern, and a range of nonmotor
symptoms precede the motor phase. The predominant early nonmotor manifestations are …

Over a period of more than 50 years, the symptomatic treatment of the motor symptoms of
Parkinson disease (PD) has been optimized using pharmacotherapy, deep brain …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Existing therapeutic strategies for managing Parkinson disease (PD), which focus on
addressing the loss of dopamine and dopaminergic function linked with degeneration of …

Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …